Literature DB >> 3111355

Therapeutic effects of imipenem-cilastatin on experimental intrauterine infections in rats.

T Hashizume, T Komatsu, Y Okumoto, M Ogashiwa, M Kemi, Z Takase.   

Abstract

The therapeutic effects of imipenem-cilastatin (MK-0787-MK-791) on experimental intrauterine infections in progesterone-treated virgin rats and postpartum rats were studied. The relative efficacy of imipenem-cilastatin for the treatment of such intrauterine infections was compared with that of cefazolin and ampicillin for the treatment of infections caused by Escherichia coli and Streptococcus faecalis, respectively. Treatment with imipenem-cilastatin significantly inhibited the proliferation of E. coli and S. faecalis in uteri, as compared with the proliferation in untreated controls. Cefazolin failed to affect the E. coli infection. With the S. faecalis infection, ampicillin effectively reduced bacterial growth, as compared with that in untreated controls. However, ampicillin was inferior to and comparable to imipenem-cilastatin in progesterone-treated virgin rats and postpartum rats, respectively. A further experiment with S. faecalis infections in rats made neutropenic by intraperitoneal injection of cyclophosphamide showed that the therapeutic effectiveness of imipenem-cilastatin was superior to that of ampicillin and was not influenced by neutropenia. Our results suggest that imipenem-cilastatin may be a useful agent for the treatment of obstetric and gynecologic infections.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3111355      PMCID: PMC174780          DOI: 10.1128/AAC.31.4.578

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Choice of antibiotics for prophylaxis or treatment of group D streptococcal endocarditis.

Authors:  P A Oill; G M Kalmanson; L R Freedman; L B Guze
Journal:  N Engl J Med       Date:  1981-07-09       Impact factor: 91.245

2.  Pharmacokinetics and bacteriological efficacy of N-formimidoyl thienamycin in experimental Escherichia coli meningitis.

Authors:  P Patamasucon; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

3.  Imipenem therapy of experimental Staphylococcus aureus and Streptococcus faecalis endocarditis.

Authors:  W M Scheld; J M Keeley
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

4.  [N-Formimidoyl-thienamycin in Animal Studies].

Authors:  W Ritzerfeld
Journal:  Arzneimittelforschung       Date:  1983

5.  Imipenem therapy of Pseudomonas aeruginosa bacteraemia in neutropenic rats.

Authors:  D E Johnson; F M Calia; M J Snyder; J W Warren; S C Schimpff
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

6.  Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin.

Authors:  J Birnbaum; F M Kahan; H Kropp; J S MacDonald
Journal:  Am J Med       Date:  1985-06-07       Impact factor: 4.965

7.  Imipenem/cilastatin in the treatment of obstetric and gynecologic infections.

Authors:  A S Berkeley; K Freedman; J Hirsch; W J Ledger
Journal:  Am J Med       Date:  1985-06-07       Impact factor: 4.965

8.  MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors:  H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

9.  Effects of ovarian hormones on manifestation of purulent endometritis in rat uteruses infected with Escherichia coli.

Authors:  Y Nishikawa; T Baba
Journal:  Infect Immun       Date:  1985-01       Impact factor: 3.441

10.  Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase.

Authors:  H Kropp; J G Sundelof; R Hajdu; F M Kahan
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.